-
Uncategorized1 month ago
AbbVie faces questions about Skyrizi competition from J&J
Threats to AbbVie’s immunology dominance took center stage on the company’s first-quarter earnings call Wednesday morning, as analysts pressed executives on their defense strategy. The heart...
-
Uncategorized1 month ago
AbbVie tops Q1 estimates, raises outlook and discontinues cancer candidate
Strong growth in immunology and neurology prompted AbbVie to raise its 2026 outlook and consider future M&A from a position of “ample financial capacity.”
-
Uncategorized1 month ago“Click Clotting” Technique Rapidly Creates Stronger Blood Clots
Researchers at McGill University have developed a rapid way to engineer blood clots that stop severe bleeding and support tissue healing more effectively. Their technique, called...
-
Uncategorized1 month agoSTAT+: Why conversations around health AI may be evolving beyond hype
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in...
-
Uncategorized1 month ago
Supply Chain Digital Twins: An Evolution, Not a Breakthrough
Digital twins help optimize drug production processes by modeling the thousands of interactions that cells, raw materials, and reagents undergo in culture. And new analysis suggests...
-
Uncategorized1 month agoTeva nabs experimental Tourette drug in $700M Emalex buyout
A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
-
Uncategorized1 month ago
Loss of Smell Therapies Informed by Olfactory Receptor Spatial Mapping
A new study published in Cell titled, “A spatial code governs olfactory receptor choice and aligns sensory maps in the nose and brain,” led by researchers from Harvard...
-
Uncategorized1 month ago
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and...
-
Uncategorized1 month ago
Bristol Myers reaches a crossroads as a make-or-break year takes shape
Bristol Myers Squibb is facing a bit of an identity crisis. CEO Chris Boerner is nearly two and a half years into his tenure, with most...
-
Uncategorized1 month ago
With growth curve trending up, Biogen looks to early-stage assets for ‘next generation’
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the pressure and cleared the way for...
